Trial Profile
Phase 1, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of CT-322 Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegdinetanib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Biomarker
- 26 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Mar 2010 Planned number of patients changed from 50 to 30 as reported by ClinicalTrials.gov.
- 17 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.